These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 29040195)
41. The Utility of Phosphohistone H3 (PHH3) in Follicular Lymphoma Grading: A Comparative Study With Ki-67 and H&E Mitotic Count. Khieu ML; Broadwater DR; Aden JK; Coviello JM; Lynch DT; Hall JM Am J Clin Pathol; 2019 May; 151(6):542-550. PubMed ID: 30788495 [TBL] [Abstract][Full Text] [Related]
42. Comparison of Three Ki-67 Index Quantification Methods and Clinical Significance in Pancreatic Neuroendocrine Tumors. Kroneman TN; Voss JS; Lohse CM; Wu TT; Smyrk TC; Zhang L Endocr Pathol; 2015 Sep; 26(3):255-62. PubMed ID: 26072124 [TBL] [Abstract][Full Text] [Related]
43. Increased Grade in Neuroendocrine Tumor Metastases Negatively Impacts Survival. Keck KJ; Choi A; Maxwell JE; Li G; O'Dorisio TM; Breheny P; Bellizzi AM; Howe JR Ann Surg Oncol; 2017 Aug; 24(8):2206-2212. PubMed ID: 28560597 [TBL] [Abstract][Full Text] [Related]
44. Grading of neuroendocrine neoplasms: mitoses and Ki-67 are both essential. van Velthuysen ML; Groen EJ; van der Noort V; van de Pol A; Tesselaar ME; Korse CM Neuroendocrinology; 2014; 100(2-3):221-7. PubMed ID: 25358267 [TBL] [Abstract][Full Text] [Related]
45. Comparison of World Health Organization 2000/2004 and World Health Organization 2010 classifications for gastrointestinal and pancreatic neuroendocrine tumors. Pasaoglu E; Dursun N; Ozyalvacli G; Hacihasanoglu E; Behzatoglu K; Calay O Ann Diagn Pathol; 2015 Apr; 19(2):81-7. PubMed ID: 25702616 [TBL] [Abstract][Full Text] [Related]
46. Redefining the Ki-67 Index Stratification for Low-Grade Pancreatic Neuroendocrine Tumors: Improving Its Prognostic Value for Recurrence of Disease. Lopez-Aguiar AG; Ethun CG; Postlewait LM; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Sarmiento JM; Kooby DA; Staley CA; Maithel SK; Cardona K Ann Surg Oncol; 2018 Jan; 25(1):290-298. PubMed ID: 29079920 [TBL] [Abstract][Full Text] [Related]
47. Twenty years of gastroenteropancreatic neuroendocrine tumors: is reclassification worthwhile and feasible? Grillo F; Albertelli M; Annunziata F; Boschetti M; Caff A; Pigozzi S; Ferone D; Mastracci L Endocrine; 2016 Jul; 53(1):58-62. PubMed ID: 26362059 [TBL] [Abstract][Full Text] [Related]
48. Multivariate analysis of metastasis‑related risk factors for patients with gastroenteropancreatic neuroendocrine tumors based on clinicopathological and endoscopic features. Tang C; Gong L; Zou W; Zhang J; Zhou Y; Wu X; Lu F; Ouyang C; Liu X Oncol Rep; 2016 Dec; 36(6):3343-3352. PubMed ID: 27748940 [TBL] [Abstract][Full Text] [Related]
50. Evaluation of the concordance between the stage of the disease and Ki-67 proliferation index in gastroenteropancreatic neuroendocrine tumors. Özaslan E; Demir S; Karaca H; Güven K Eur J Gastroenterol Hepatol; 2016 Jul; 28(7):836-41. PubMed ID: 26945127 [TBL] [Abstract][Full Text] [Related]
51. Clinicopathologic Features of Gastroenteropancreatic Neuroendocrine Tumors: A Single-center Experience. Akın Telli T; Esin E; Yalçın Ş Balkan Med J; 2020 Aug; 37(5):281-286. PubMed ID: 32573179 [TBL] [Abstract][Full Text] [Related]
52. Pancreatic neuroendocrine tumors: accurate grading with Ki-67 index on fine-needle aspiration specimens using the WHO 2010/ENETS criteria. Farrell JM; Pang JC; Kim GE; Tabatabai ZL Cancer Cytopathol; 2014 Oct; 122(10):770-8. PubMed ID: 25044931 [TBL] [Abstract][Full Text] [Related]
53. Synaptophysin-Ki67 double stain: a novel technique that improves interobserver agreement in the grading of well-differentiated gastrointestinal neuroendocrine tumors. Matsukuma K; Olson KA; Gui D; Gandour-Edwards R; Li Y; Beckett L Mod Pathol; 2017 Apr; 30(4):620-629. PubMed ID: 28084345 [TBL] [Abstract][Full Text] [Related]
54. Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications. Fazio N; Milione M Cancer Treat Rev; 2016 Nov; 50():61-67. PubMed ID: 27636009 [TBL] [Abstract][Full Text] [Related]
55. Grading of neuroendocrine tumors with Ki-67 requires high-quality assessment practices. Remes SM; Tuominen VJ; Helin H; Isola J; Arola J Am J Surg Pathol; 2012 Sep; 36(9):1359-63. PubMed ID: 22895268 [TBL] [Abstract][Full Text] [Related]
56. Re-evaluation of cases with gastroenteropancreatic neuroendocrine tumors between 2004 and 2012 according to the 2010 criteria. Ozkara S; Aker F; Yesil A; Senates E; Canbey C; Yitik A; Gonen C Hepatogastroenterology; 2013 Oct; 60(127):1665-72. PubMed ID: 24627925 [TBL] [Abstract][Full Text] [Related]
59. G3 GEP NENs category: are basic and clinical investigations well integrated? Milione M; Fazio N Endocrine; 2018 Apr; 60(1):28-30. PubMed ID: 28733935 [TBL] [Abstract][Full Text] [Related]
60. Recent classifications systems for gastroenteropancreatic neuroendocrine tumors A single-center experience. Yagmur Y; Söğutcü N; Gümüş S Ann Ital Chir; 2020; 91():598-604. PubMed ID: 32989209 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]